BioCryst Pharmaceuticals, Inc. (BCRX) vs Fortrea Holdings Inc. (FTRE)
A side-by-side comparison of BioCryst Pharmaceuticals, Inc. and Fortrea Holdings Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCRX
BioCryst Pharmaceuticals, Inc.
$8.10HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
FTRE
Fortrea Holdings Inc.
$21.11HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BCRX vs FTRE
growth of $100 · dividends reinvested · last 3yBCRX -8.1% (-2.8%/yr)FTRE -34.0% (-12.9%/yr)BCRX compounded faster over this window
BCRX FTRE
BCRX vs FTRE: by the numbers
- •BCRX is the larger company ($2.06B vs $2.01B market cap).
- •Both run net losses; FTRE's is the smaller (-3.18% vs -40.90% net margin).
- •BCRX grew revenue faster over the past five years (64.07% vs 1.09% CAGR).
Metrics side by side
Valuation
| Metric | BCRX | FTRE |
|---|---|---|
| Forward P/E | N/A | 25.10 |
| P/S ratio | 2.19 | 0.75 |
| P/B ratio | N/A | 3.83 |
| EV / EBITDA | N/A | 33.11 |
| FCF yield | 17.35% | 7.50% |
Profitability
| Metric | BCRX | FTRE |
|---|---|---|
| Gross margin | 97.82% | 17.11% |
| Operating margin | 38.98% | 0.41% |
| Net margin | -40.90% | -3.18% |
| ROE | N/A | -16.25% |
| ROIC | -89.73% | 0.62% |
Growth (annualized)
| Metric | BCRX | FTRE |
|---|---|---|
| Revenue CAGR (5Y) | 64.07% | 1.09% |
| FCF CAGR (5Y) | N/A | -12.98% |
| Total return CAGR (5Y) | -10.02% | N/A |
Frequently asked
- Which has grown faster, BCRX or FTRE?
- Over the past five years, BCRX grew revenue faster — BCRX at a 64.07% CAGR versus FTRE at 1.09%.
Go deeper
Dig into the metrics
BioCryst Pharmaceuticals ROEFortrea ROEBioCryst Pharmaceuticals operating marginFortrea operating marginBioCryst Pharmaceuticals revenue growthFortrea revenue growthBioCryst Pharmaceuticals free cash flowFortrea free cash flow
BioCryst Pharmaceuticals & Fortrea appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.